People · Operator
Named in public records as an officer, director or promoter · active 2017–2022 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| DoubleRainbow Biosciences Inc. | — | Biotechnology | Series A | $15.0M | $310.0M | 2019 |
| Kairos Pharma, LTD. | — | Pharmaceuticals | Seed | $4.2M | $12.5M | 2022 |
| H3D, Inc. | — | Other | Seed | $2.8M | $52.0M | 2017 |
John Yu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Yu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Feng Zhang | 1 | 3 |
| Hyun W. Bae | 1 | 2 |
| Zhong He | 1 | 2 |
| Doug Samuelson | 1 | 2 |
| Hyun Bae | 1 | 2 |
| John S. Yu | 1 | 2 |
| Neil Bhowmick | 1 | 1 |
| Ramachandran Murali | 1 | 1 |
| Tian Xu | 1 | 1 |
| Jing-Ke Weng | 1 | 1 |
| Wei Gong | 1 | 1 |
| Jiangtao Yu | 1 | 1 |
| Wan Yu | 1 | 1 |
| Neil S. Bhowmick | 1 | 1 |
| Hansoo Michael W. Keyoung | 1 | 1 |
| Ramachandran S. Murali | 1 | 1 |
| Doug S. Samuelson | 1 | 1 |
| Rahul W. Singhvi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.